Articles

This sweet treat may be future aid in diabetes treatment.

Medication showed significant reduction in risk for cardiovascular death, hospitalization for worsening heart failure.

Study finds connection between duration of therapy in senior patients and development of neurodegenerative disease.

When it comes to antidiabetic therapies, professionals should be aware of safety concerns with concentrated insulin formulations, metformin and renal function, and SGLT-2 inhibitors and DKA. See the breakdown of these safety issues by Tom Palma, RPh, MS, BCPS, and Greg Wiggers, PharmD, PhD, plus exclusive commentary by DIC Advisory Board member Dr. George Bakris.

Study shows age-related comorbidities decreased in males over 65 who take metformin.

Study looks at the heterogeneity of CKD in type 1 diabetes.

The risks may be outweighing the benefits, but only to a point.

Big changes to affect small vessels.

Proper training key to best results in both groups.

Race, socioeconomic status thought reasons behind lack of adherence to the recommendations.